Skip to main content
// //
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Thinking about trading options or stock in Apple, Boeing, Moderna, ServiceNow, or Zoom Video?
- PR Newswire - Mon Oct 26, 8:31AM CDT
PR Newswire - PRNW
Mon Oct 26, 8:31AM CDT
NEW YORK , Oct. 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, BA, MRNA, NOW, and ZM.
Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)
- BusinessWire - Mon Oct 26, 6:00AM CDT
BusinessWire - CMTX
Mon Oct 26, 6:00AM CDT
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna's vaccine candidate against COVID-19, to support the Ministry's ongoing efforts to secure early access to a safe and effective COVID-19 vaccine for the people of Qatar.
Thinking about trading options or stock in Moderna, General Electric, Walt Disney, F5 Networks, or Capital One?
- PR Newswire - Fri Oct 23, 8:31AM CDT
PR Newswire - PRNW
Fri Oct 23, 8:31AM CDT
NEW YORK , Oct. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, GE, DIS, FFIV, and COF.
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
- BusinessWire - Thu Oct 22, 8:47AM CDT
BusinessWire - CMTX
Thu Oct 22, 8:47AM CDT
--Moderna thanks PPD, its CRO partner, for the successful execution of COVE Study enrollment
Thinking about trading options or stock in Moderna, Procter & Gamble, Microsoft, AT&T, or NVIDIA?
- PR Newswire - Tue Oct 20, 8:31AM CDT
PR Newswire - PRNW
Tue Oct 20, 8:31AM CDT
NEW YORK , Oct. 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, PG, MSFT, T, and NVDA.
2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium (Virtual)
- BusinessWire - Mon Oct 19, 9:00AM CDT
BusinessWire - CMTX
Mon Oct 19, 9:00AM CDT
Join us as we discuss today's pressing healthcare issues.
Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
- BusinessWire - Thu Oct 15, 3:15PM CDT
BusinessWire - CMTX
Thu Oct 15, 3:15PM CDT
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.
Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)
- BusinessWire - Wed Oct 14, 7:00AM CDT
BusinessWire - CMTX
Wed Oct 14, 7:00AM CDT
Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has received written confirmation from the European Medicine Agency (EMA) that mRNA-1273, the Company's vaccine candidate against COVID-19, is eligible for submission of an application for a European Union Marketing Authorization under the Agency's centralized procedure. Confirmation of eligibility was given in response to the submission of a letter of intent enabling Moderna to evaluate the opportunity for submitting a Marketing Authorization Application (MAA) for mRNA-1273 with the EMA. This submission follows positive results from a preclinical viral challenge study and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in the New England Journal of Medicine.
Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)
- BusinessWire - Tue Oct 13, 10:04AM CDT
BusinessWire - CMTX
Tue Oct 13, 10:04AM CDT
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company's vaccine candidate against COVID-19. This initiation follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in the New England Journal of Medicine.
Thinking about trading options or stock in Xilinx, Moderna, NXP Semiconductors, Carnival Corp, or MGM Resorts?
- PR Newswire - Fri Oct 9, 8:31AM CDT
PR Newswire - PRNW
Fri Oct 9, 8:31AM CDT
NEW YORK , Oct. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XLNX, MRNA, NXPI, CCL, and MGM.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies